Cost-utility analysis of the treatment of relapsing-remitting multiple sclerosis with glatiramer acetate or interferon beta in Spain

被引：0
|
作者：
Rubio-Terrés, C
Medina, F
Aristegui, I
Izquierdo, G
机构：
[1] Aventis Pharma SA, Madrid, Spain
[2] Hosp Univ Virgen Macarena, Seville, Spain
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)64043-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：277 / 277
页数：1
相关论文
共 50 条
  • [31] Gene Expression Biomarkers for Glatiramer Acetate Treatment Response in Relapsing-Remitting Multiple Sclerosis
    Anis, Saar
    Sonis, Polina
    Hanael, Erez
    Gurevich, Michael
    Achiron, Anat
    NEUROLOGY, 2013, 80
  • [32] COST-UTILITY ANALYSIS OF DISEASE-MODIFYING DRUGS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN IRAN
    Imani, A.
    Golestani, M.
    Tabrizi, J. S.
    Janati, A.
    VALUE IN HEALTH, 2013, 16 (07) : A624 - A624
  • [33] COST-UTILITY ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMERATE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN PORTUGAL
    Silva Miguel, L.
    de Sa, J.
    Pinheiro, B.
    Acosta, C.
    VALUE IN HEALTH, 2015, 18 (07) : A758 - A758
  • [34] DIMETHYL FUMARATE VERSUS FINGOLIMOD AND TERIFLUNOMIDE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA: A COST-UTILITY ANALYSIS
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A194 - A194
  • [35] Cost-Utility Analysis Comparing Ocrelizumab vs Rituximab in the Treatment of Relapsing-Remitting Multiple Sclerosis: The Colombian Perspective
    Navarro, Cristian E.
    Betancur, John E.
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 83 - 91
  • [36] COST-UTILITY ANALYSIS OF ALEMTUZUMAB VERSUS NATALIZUMAB FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: US PAYER PERSPECTIVE
    Smith, A.
    Hashemi, L.
    Ma, I
    VALUE IN HEALTH, 2016, 19 (07) : A431 - A431
  • [37] The use of interferon beta in relapsing-remitting multiple sclerosis
    Etheridge, LJ
    Beverley, DW
    Ferrie, C
    McManus, E
    ARCHIVES OF DISEASE IN CHILDHOOD, 2004, 89 (08) : 789 - 791
  • [38] Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
    Cocco, Eleonora
    Marrosu, Maria Giovanna
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 759 - 766
  • [39] B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
    Tacke, Sabine
    Braune, Stefan
    Rovituso, Damiano M.
    Ziemssen, Tjalf
    Lehmann, Paul, V
    Dikow, Heidi
    Bergmann, Arnfin
    Kuerten, Stefanie
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (03):
  • [40] Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis
    K. O'Rourke
    C. Walsh
    M. Hutchinson
    Journal of Neurology, 2007, 254 : 1547 - 1554
12345